BiotechTube
Postsurgical Therapeutics

Postsurgical Therapeutics

San Francisco, United States· Est.
pstherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Postsurgical Therapeutics is a private, pre-revenue biotech founded in 2014, leveraging its PLGA-based drug delivery platform to create locally administered, repurposed drugs. Its lead program, the CLOTT platform, targets advanced cancers via intra-tumor injection combined with systemic therapy, while other partnered programs address pain in hemophilic arthropathy and diabetic neuropathy. The company operates with a semi-virtual model under experienced leadership, having previously monetized assets through sales to Korean partners.

OncologyPain Management

Technology Platform

Sustained and controlled drug delivery system (DDS) using biodegradable PLGA (polylactic glycolic acid) polymers, formulated as microspheres (MS) and in situ gelling (ISG) systems. The platform allows for tunable, localized release of therapeutics to minimize systemic side effects.

Opportunities

The company's platform enables the repurposing of known drugs for new, localized indications, potentially accelerating development timelines and reducing regulatory risk.
Orphan drug designation for its hemophilia pain project offers market exclusivity and development support.
The growing focus on targeted, patient-friendly therapies in oncology and chronic pain presents a significant market entry point.

Risk Factors

The company is at a pre-clinical stage with unproven clinical efficacy for its lead programs.
Its semi-virtual model and pre-revenue status create dependency on securing partnership funding or additional investment to advance development.
The competitive landscape for drug delivery and repurposed drugs is intense, with many well-funded players.

Competitive Landscape

Postsurgical competes in the crowded drug delivery and drug repurposing space. Its specific focus on localized PLGA delivery for oncology and pain places it against other specialty pharma and biotech companies developing sustained-release formulations. Larger pharmaceutical companies with internal drug delivery capabilities also represent significant competition.

More companies in Drug Delivery & Formulation →More companies in United States →